There are a couple of interesting articles in this week’s print issue of The Economist, but they are both premium content on the web, so I’ve dug a bit deeper for you and will post on them separately. One article contrasts the global shortage of opiates for medical use with the efforts being made to stop Afghani farmers growing the opium poppy for the heroin trade. A crazy situation. One possible solution is licensing farmers to grow the crop under strict controls, but that is not without difficulties, especially in a place like Afghanistan. However, there is a possible scientific solution. It turns out that Tasmania, of all places, is an important opium poppy producer, and researchers at “Tasmanian Alkaloids recognised that there was a possibility of breeding a poppy variety in which the biosynthetic pathway stopped at thebaine instead of going on to produce morphine.” That would make it ok for therapeutic opiate production but useless for the illicit drug trade. You can read all about it here. There’s a paper on poppy transformation here and one on poppy genetic diversity here.
Project Baseline
The work at UV Irvine summarized here on the genetic effects of climate change on different kinds of plants is interesting enough. But what particularly intrigued me was the reference to a Project Baseline, “a national effort to collect and preserve seeds from contemporary plant populations.” Unfortunately I was not able to find anything more about this on the internet. Anyway, sounds like they need something similar in Armenia.
Stiffing it to the Maca patent
Maca (Lepidium meyenii) is in the news again thanks to a report from Associated Press. (There’s a version here, and many others around the place.) The gist of the article is that a US patent on Maca’s libido-enhancing compounds, granted to PureWorld Botanicals in 2001, is not valid. “Peruvian officials called the patent an ’emblematic case’ of biopiracy and are preparing to challenge it in U.S. courts,” the report says. It goes on to examine other cases of biopiracy and the use by pharmaceutical companies of compounds found in nature.
Farming Hoodia
Another example of a wild species being farmed: this article in the San Francisco Chronicle tells the story of Hoodia gordonii cultivation in southern Africa. The species is the source of a hunger suppressant which Unilever has been licensed to commercialize, with a royalty payment going to San tribesmen. Another Hoodia species may have potential as a salad vegetable. Prices are such that there is a thriving smuggling trade in wild-harvested product. Some Namibian farmers are trying to cultivate the plant – organically – but it is not easy.
Ancient Greek wine
Check out this interesting article on the surprising properties of some of the wines produced in some regions of ancient Greece as a result of the addition of various herbs. I wonder if there is enough information in the relevant texts to reproduce some of these concoctions.